Major Depressive Disorder (MDD) Treatment Market
Major Depressive Disorder (MDD) is one of the most common mental disorder characterized by persistent and tenacious low mood that interferes with the person’s ability to work, eat, sleep and normal activities. MDD is also referred as clinical depression, major depression, and unipolar depression or as recurrent depression. The common symptoms associated with this disorder include insomnia, loss of interest, recurrent thoughts of death, feelings of worthlessness and reduced ability to think. Increasing number of patients suffering from MDD has grabbed the attention of MDD drugs manufacturer to invest into MDD treatment market.
Major Depressive Disorder (MDD) is one of the most common mental disorder characterized by persistent and tenacious low mood that interferes with the person’s ability to work, eat, sleep and normal activities. MDD is also referred as clinical depression, major depression, and unipolar depression or as recurrent depression. The common symptoms associated with this disorder include insomnia, loss of interest, recurrent thoughts of death, feelings of worthlessness and reduced ability to think. Increasing number of patients suffering from MDD has grabbed the attention of MDD drugs manufacturer to invest into MDD treatment market.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Report Description<br />
<strong>MDD</strong> treatment market is expected to register healthier CAGR in emerging markets such<br />
as India, China, and Brazil compared to other developed regions in the world.<br />
<strong>Major</strong> <strong>Depressive</strong> <strong>Disorder</strong> (<strong>MDD</strong>) <strong>Treatment</strong> <strong>Market</strong>: Key Players<br />
Key companies operational in <strong>MDD</strong> treatment market are Eli Lilly and Company, Johnson<br />
& Johnson, Pfizer, Inc., AstraZeneca plc, Merck & Co., GlaxoSmithKline plc, Sanofi S.A.,<br />
Shire plc, Novartis AG, Janssen Pharmaceutical, Inc., and others.<br />
Browse full report: http://www.futuremarketinsights.com/reports/major-depressivedisorder-treatment-market
Change language